AZRX News and Press, AzurRx BioPharma Inc. From 03/21/19

The following slide deck was published by AzurRx BioPharma, Inc. in conjunction with this Read more ...

Thinly traded nano cap AzurRx BioPharma (NASDAQ: AZRX ) is up  20%  premarket on increased volume on the heels of positive results from a Phase 2 clinical tria l evaluating lead drug MS1819-SD in chronic pancreatitis patients with exocrine pancreatic insufficiency. The data are ...

NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that a present...

Noteworthy events during the week of March 17 - 23 for healthcare investors. More news on: SCYNEXIS, Inc., Sage Therapeutics, Inc., Intrexon Corporation, Healthcare stocks news, , Read more ...

BROOKLYN, N.Y., March 15, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc.(NASDAQ: AZRX ) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the Company wil...

NEW YORK, March 12, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced a poster prese...

Dosing is underway in a Phase 2 clinical trial, OPTION , evaluating AzurRx BioPharma's ( AZRX +30% ) MS1819-SD in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency , a deficiency in pancreatic enzymes that prevents normal food digestion. More news on: AzurRX Biopha...

Gainers:  Kandi Technologies Group (NASDAQ: KNDI ) +47% . LeMaitre Vascular (NASDAQ: LMAT ) +28% . AzurRx BioPharma (NASDAQ: AZRX ) +29% . Blink Charging (NASDAQ: BLNK ) +21% . Carrols Restaurant Group (NASDAQ: TAST ) +17% . OneSpan (NASDAQ: OSPN ) +17% . Garmin (NASDAQ: GRMN ) ...

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, this morning issued a clinical development and strategic corporate update. In the update, the company reports that the first patients have been dosed...

First patients dosed in open-label, cross-over Phase II OPTION study with MS1819-SD for exocrine pancreatic insufficiency in cystic fibrosis. Five clinical trial sites in the U.S. activated for OPTION study Additional European sites now expected with Ministry of Health approval ...